CYAN: Cyanotech Corporation Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 2.74
Enterprise Value ($M) 9.97
Book Value ($M) 9.50
Book Value / Share 1.32
Price / Book 0.29
NCAV ($M) -3.90
NCAV / Share -0.54
Price / NCAV -0.70

Profitability (mra)
Return on Invested Capital (ROIC) -0.22
Return on Assets (ROA) -0.17
Return on Equity (ROE) -0.34

Liquidity (mrq)
Quick Ratio 0.28
Current Ratio 1.06

Balance Sheet (mrq) ($M)
Current Assets 10.55
Assets 23.96
Liabilities 14.46
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Effect Of Dilutive Securities n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
10-03 13D/A Davis Michael A / 25.00 5.18

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-06-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2024 ☐ Transition Report Pursuant to Section

(click for more detail)

Similar Companies
CUBT – Curative Biotechnology, Inc. CURLF – Curaleaf Holdings, Inc.
CVSI – CV Sciences, Inc. CYDY – CytoDyn Inc.
DBVTF – DBV Technologies S.A.


Financial data and stock pages provided by
Fintel.io